Dailypharm Live Search Close

GC Pharma, the most likely company to produce Covivak

By Nho, Byung Chul | translator Choi HeeYoung

21.07.06 11:10:00

°¡³ª´Ù¶ó 0
MPC to acquire shares in Pharm Bio-tech, Russia

Technology transfer by September

Production and sales are expected around October


Chumakov Institute recently visited Andong Animal Cell Verification Support Center. Russia's Covivak is likely to be produced in domestic CMOs.

According to industries, MPC, which is a South Korean corporation to introduce Covivak, recently signed a contract with Pharm Bio-tech, a Russian company that has rights to produce and publish in Russia, to acquire shares (37.5%). Among the domestic companies that invested in securing the stake, Wellbiotec, HumanN, and Nexton Bio became Pharm Bio-tech shareholders.

MPC is also expected to establish a joint venture for Pharm Bio-tech and Covivak production, sales, and distribution in Korea to run vaccine businesses for ASEAN countries.

Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)